Oral pill aims to keep blood cancer at bay after risky transplant
NCT ID NCT06297629
Summary
This study aimed to test if an oral drug called ASTX727, given alone or with an infusion of donor immune cells, could help control blood cancers like leukemia after a stem cell transplant. It was designed for adults who had received a transplant but were at high risk of their cancer returning. The main goals were to see if the treatment was safe and if it could help keep patients cancer-free longer. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.